MRI引导活检评估半腺体冷冻消融治疗临床显著前列腺癌的中期随访
本研究采用MRI/超声融合活检全面评估半腺体冷冻消融作为临床显著前列腺癌(Grade Group≥2)主要治疗的成功率。61例单侧癌患者中,6个月随访82%(50/61)无活检可检测的临床显著癌,18个月随访82%(22/27)仍为阴性。仅1例出现对侧新病灶,无Clavien-Dindo 2级以上不良事件。
要点
- 半腺体冷冻消融后6个月82%患者无临床显著癌残留
- 18个月中期随访82%患者仍保持活检阴性
- 联合靶向、系统采样和原阳性位点追踪可最大化检出
核心结论
- 半腺体冷冻消融经MRI引导活检全面评估,可在82%的临床显著前列腺癌患者中消除癌灶,且疗效至少维持18个月。
研究设计与样本
- 开放标签试验(NCT03503643)纳入61例单侧临床显著前列腺癌(Grade Group≥2)患者,接受初次半腺体冷冻消融。
- 患者80%为白人,平均年龄69岁,PSA 6.6 ng/ml,前列腺体积38 cc。
- 治疗前及随访6个月(61例)、18个月(27例)时采用MRI/超声融合活检,结合靶向、系统采样及原阳性位点追踪。
主要发现
- 6个月随访时82%(50/61)患者无活检可检测的临床显著前列腺癌。
- 18个月随访时82%(22/27)患者仍保持活检阴性。
- 随访期间仅1/27例发现对侧前列腺新癌灶。
- 未发生Clavien-Dindo 2级以上不良事件。
关键数值与推荐
- 主要终点为活检检测到的临床显著前列腺癌。
- 联合靶向活检、模板系统采样和原阳性位点追踪三种采样方法可最大化癌症检出。
临床怎么用
- 半腺体冷冻消融可作为单侧临床显著前列腺癌的 primary 治疗选择之一。
- 术后随访应采用MRI/超声融合活检,并联合靶向、系统采样及原阳性位点追踪以全面评估疗效。
局限性
- 18个月随访样本量较小(27例),长期疗效需进一步验证。
- 研究为开放标签单臂试验,缺乏对照组。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Contemporary biopsy methods were used to determine the success rate of hemigland cryoablation as a primary treatment for prostate cancer. Previous studies, often including men at low risk, have used magnetic resonance imaging guided biopsy to a variable extent. Here, we uniformly used the new diagnostic modality to study all men, each with clinically significant cancer, at baseline and at short and intermediate-term followup. MATERIALS AND METHODS: In an open label trial (NCT03503643) 61 men with unilateral cancer (all clinically significant, ie Grade Group 2 or greater) underwent primary hemigland cryoablation. Subjects were 80% Caucasian, average age 69 years, prostate specific antigen 6.6 ng/ml and prostate volume 38 cc. Biopsy was performed using magnetic resonance imaging/ultrasound fusion prior to treatment and at the followup intervals of near-term (6 months, in 61) and intermediate-term (18 months, in 27). All utilities of fusion biopsy, ie targeting of magnetic resonance imaging visible lesions, template systematic sampling, and in followup, tracking of prior positive sites, were used throughout the study to detect clinically significant cancer, the primary end point. RESULTS: Following treatment 82% of men (50 of 61) had no biopsy detectable clinically significant prostate cancer at 6-month near-term followup and 82% of men (22 of 27) reaching the 18-month intermediate-term remained biopsy negative. Combination of the 3 sampling methods provided maximal cancer detection. During followup a new focus of cancer was found in the contralateral prostate in only 1 of 27 men. No adverse events above Clavien-Dindo grade 2 were encountered. CONCLUSIONS: Hemigland cryoablation, when rigorously evaluated by all utilities of magnetic resonance imaging guided biopsy, appears to eliminate clinically significant cancer in 82% of men, a success rate that endures for at least 18 months.
引用
- Chuang R, Kinnaird A, Kwan L, et al. Hemigland Cryoablation of Clinically Significant Prostate Cancer: Intermediate-Term Followup via Magnetic Resonance Imaging Guided Biopsy. J Urol. 2020. PMID: 32985924. doi:10.1097/JU.0000000000001133
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。